Apaziquone

Drug Profile

Apaziquone

Alternative Names: EO 9; EOquin; Neoquin; NOR 701; NSC 382456; Qapzola

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Spectrum Pharmaceuticals
  • Developer Handok Inc; Nippon Kayaku; Spectrum Pharmaceuticals
  • Class Aziridines; Cytostatic antibiotics; Indolequinones
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer

Most Recent Events

  • 14 Aug 2017 Spectrum Pharmaceuticals initiates enrolment in a phase III trial for Bladder cancer in USA
  • 25 Jul 2017 Spectrum Pharmaceuticals plans a phase III trial for Bladder cancer (Adjuvant therapy) (NCT03224182)
  • 08 Mar 2017 Spectrum Pharmaceuticals plans a phase III trial for Bladder cancer (Adjuvant therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top